Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALAD | P13716 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | EPRS1 | P07814 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6667136 | 0.84 | MAPT (0.51) | ALADMCL1RXFP1 | |
| SCHEMBL6843818 | 0.84 | TP53 (0.44) | — | |
| SCHEMBL28093059 | 0.83 | CA12 (0.49) | RXFP1 | |
| SCHEMBL6740513 | 0.83 | ALAD (0.51) | ALADMCL1 | |
| SCHEMBL15083062 | 0.81 | MAPK14 (0.43) | — | |
| SCHEMBL4553247 | 0.79 | PPARD (0.44) | — | |
| SCHEMBL15083064 | 0.75 | HCAR2 (0.43) | ALAD | |
| SCHEMBL8842795 | 0.73 | KMO (0.55) | — | |
| SCHEMBL27768493 | 0.73 | TP53 (0.41) | — | |
| SCHEMBL8843416 | 0.72 | KMO (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | WARNER-LAMBERT COMPANY LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004014381-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS | WARNER-LAMBERT COMPANY LLC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014381-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS | WARNER-LAMBERT COMPANY LLC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | MMP13, MMP3, MMP26 | ALAD 2498/4885MCL1 913/4885PTPN1 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.